Ionis Pharmaceuticals Inc
Company Profile
Business description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Contact
2855 Gazelle Court
CarlsbadCA92010
USAT: +1 760 931-9200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
927
Stocks News & Analysis
stocks
5 undervalued US stocks that crushed earnings
stocks
Global healthcare stocks for your watchlist
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,901.35 | 22.89 | 0.29% |
| DAX 40 | 24,533.74 | 15.82 | -0.06% |
| Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
| FTSE 100 | 8,956.49 | 89.47 | 1.01% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,611.34 | 192.87 | 0.94% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,263.26 | 37.74 | 0.61% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |